Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies

被引:13
作者
Chen, Jinliang [1 ]
Lou, Honggang [1 ]
Jiang, Bo [1 ]
Shao, Rong [1 ]
Yang, Dandan [1 ]
Hu, Yin [1 ]
Xu, Yichao [1 ]
Ruan, Zourong [1 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Clin Pharmacol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China
关键词
food effect; gender difference; pharmacokinetics; rosuvastatin; safety; ETHNIC VARIABILITY; DRUG; TRANSPORTERS; OATP1B1; SAFETY; WHITE;
D O I
10.1002/cpdd.706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of food and gender on the pharmacokinetics of rosuvastatin in healthy Chinese subjects were investigated from 4 bioequivalence studies. These studies were designed as randomized, open-label, and 2-period crossover in both fasting and fed states. A total of 204 subjects were enrolled, 134 men and 70 women. These subjects received a single oral 10-mg dose of rosuvastatin with a 7-day washout between 2 periods. The plasma concentrations were determined using a validated liquid chromatography tandem mass spectrometry method, and pharmacokinetic parameters were calculated by noncompartmental methods. Compared with the fasting condition, administration after a high-fat and high-calorie meal resulted in an approximately 40% reduction of rosuvastatin exposure and a near 50% decrease in absorption rate. Moreover, the apparent clearance was significantly greater in the fed state than that in the fasting state. It was noted that the adverse events incidence is increased by approximately 30% in the fasting state; however, no serious adverse events were observed. Additionally, small differences in pharmacokinetic characteristics were found between male and female subjects. Food effect might be considered for optimal effectiveness and safety of rosuvastatin therapy.
引用
收藏
页码:235 / 245
页数:11
相关论文
共 26 条
[1]   Lipid-lowering efficacy of rosuvastatin [J].
Adams, Stephen P. ;
Sekhon, Sarpreet S. ;
Wright, James M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11)
[2]   Rosuvastatin: Beyond the cholesterol-lowering effect [J].
Cortese, Francesca ;
Gesualdo, Michele ;
Cortese, Annamaria ;
Carbonara, Santa ;
Devito, Fiorella ;
Zito, Annapaola ;
Ricci, Gabriella ;
Scicchitano, Pietro ;
Ciccone, Marco Matteo .
PHARMACOLOGICAL RESEARCH, 2016, 107 :1-18
[3]   A Review of Food-Drug Interactions on Oral Drug Absorption [J].
Deng, Jianyuan ;
Zhu, Xiao ;
Chen, Zongmeng ;
Fan, Chun Ho ;
Kwan, Him Shek ;
Wong, Chi Ho ;
Shek, Ka Yi ;
Zuo, Zhong ;
Lam, Tai Ning .
DRUGS, 2017, 77 (17) :1833-1855
[4]   Bioequivalence Study Methods with Pharmacokinetic Endpoints for Topical Ophthalmic Corticosteroid Suspensions and Effects of Subject Demographics [J].
Harigaya, Yoriko ;
Jiang, Xiaojian ;
Zhang, Hongling ;
Chandaroy, Parthapratim ;
Stier, Ethan M. ;
Pan, Yuzhuo .
PHARMACEUTICAL RESEARCH, 2019, 36 (01)
[5]   Statin safety: Lessons from new drug applications for marketed statins [J].
Jacobson, TA .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :44C-51C
[6]   Narrative Review: Statin-Related Myopathy [J].
Joy, Tisha R. ;
Hegele, Robert A. .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (12) :858-U63
[7]   Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin [J].
Kitamura, Satoshi ;
Maeda, Kazuya ;
Wang, Yi ;
Sugiyama, Yuichi .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (10) :2014-2023
[8]   Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor [J].
Kubitza, Dagmar ;
Becka, Michael ;
Mueck, Wolfgang ;
Halabi, Atef ;
Maatouk, Haidar ;
Klause, Norbert ;
Lufft, Volkmar ;
Wand, Dominic D. ;
Philipp, Thomas ;
Bruck, Heike .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) :703-712
[9]   Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment [J].
Lee, E ;
Ryan, S ;
Birmingham, B ;
Zalikowski, J ;
March, R ;
Ambrose, H ;
Moore, R ;
Lee, C ;
Chen, YS ;
Schneck, D .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) :330-341
[10]   Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood [J].
Liu, Z. ;
Martin, J. ;
Orme, L. ;
Seddon, B. ;
Desai, J. ;
Nicholls, W. ;
Thomson, D. ;
Porter, D. ;
McCowage, G. ;
Underhill, C. ;
Cranswick, N. ;
Michael, M. ;
Zacharin, M. ;
Herschtal, A. ;
Sivasuthan, J. ;
Thomas, D. M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (05) :887-898